

Outperform → | Target Price : € 16.0

Price (26/05/2025) : € 12.10 | Upside : 32%


Révision

12/25e 12/26e

EPS

Q1 2025 - Higher number of partners drive net sales and earnings

Publication date: 27/05/2025 06:00 Writing date: 26/05/2025 15:03



Sources: ODDO BHF Securities, SIX

Share data		
TPG GY TPGG.DE		
Market Cap (€m)		247
Enterprise value (€m)		358
Extrema 12 months (€)	7.20 _	12.10
Free Float (%)		20.1

Performance (%)	1m	3m	12m
Absolute	38.8	40.7	38.4
Perf. rel. Country Index	27.5	48.5	45.0
Perf. rel. SDAX	30.4	27.9	26.2

P&L	12/25e	12/26e	12/27e
Sales (€m)	690	802	839
EBITDA (€m)	69.2	60.0	65.0
Current EBIT (€m)	59.3	50.1	55.0
Attr. net profit (€m)	40.1	27.3	30.8
Adjusted EPS (€)	1.96	1.34	1.51
Dividend (€)	0.00	0.00	0.00
P/E (x)	6.2	9.0	8.0
P/B (x)	1.2	1.1	0.9
Dividend Yield (%)	0.0	0.0	0.0
FCF yield (%)	9.5	12.3	12.3
EV/Sales (x)	0.52	0.44	0.42
EV/EBITDA (x)	5.2	5.9	5.4
EV/Current EBIT (x)	6.0	7.1	6.4
Gearing (%)	51	46	39
Net Debt/EBITDA (x)	1.6	1.8	1.6

Next Events	
26/06/2025	Annual General Meeting
22/08/2025	H1 Results
14/11/2025	O2 Posults

Key figures above estimates

For the first three months of 2025, TPG has reported GMV (gross merchandise volume), net sales and adj. EBITDA that beat out estimates. GMV rose by almost 87% to \leqslant 356.3m (+10.3% vs ODDO BHFe) and net sales by 49% to \leqslant 160.8m (+1.2% vs. ODDO BHFe). Organic growth was 59% in Q1 2025 (vs. 43% in FY 2024). The growth in GMV and net sales was driven by the increase in number of connected partners to 15,348 (Q1 2024: 11,987) and the successful expansion of the platform and software solutions to 26 sectors. The company made four acquisitions in Q1 2025 (Lyra Pet, Fintus, Herbertz, JoliCloset), of which the Lyra Pet and Herbertz acquisitions were already consolidated in the reporting period. The number of active customers increased by 29.5% to 5.7m and the order volume by 67% to 1.5m. As a result, adj. EBITDA rose by 87.1% to \leqslant 15.9m (+9.9% vs ODDO BHFe).

Q1 2025 Resu	lts				
€m	Q1 2025	Q1 2024	Ү-о-у	ODDO BHFe	Δ
Net sales	160.8	107.9	+49.0%	158.8	+1.2%
Adj. EBITDA	15.9	8.5	+87.1%	14.5	+9.9%
Margin	9.9%	7.9%	+200bp	9.1%	+80bp
GMV	356.3	190.6	+86.9%	322.9	+10.3%

Sources: ODDO BHF Securities, company

2025 guidance and medium-term planning confirmed

As we had expected, TPG confirmed its forecast for 2025 (GMV of € 1.3bn, net sales of between € 680m and € 700m, adj. EBITDA of between € 47m and € 50m) and the medium-term planning (GMV of € 1.6bn, net sales of at least € 820m, adj. EBITDA margin of between 7% and 10%) which relates to the 2026 financial year.

For 2025e, we are in line with company guidance and consensus.

For 2026e, we are slightly below GMV (ODDO BHFe: € 1.52bn) and net sales (ODDO BHFe: € 802.4m), but in line with adj. EBITDA margin (ODDO BHFe: 7.5%).

Profitable growth ahead. Outperform rating maintained

In our view, TPG has made a good start to the financial year and together with the four aforementioned acquisitions, the company is at the beginning of a long-term growth strategy which should lead to higher sales and earnings. We confirm our Outperform recommendation and target price of € 16.

Klaus Breitenbach (Analyst) +49 (0) 69 718 1011 klaus.breitenbach@oddo-bhf.com

Page 1/5

Conflict of interests:

ODDO BHF SCA and/or one of its subsidiaries could be in a conflict of interest situation with one or several of the issuers mentioned in this publication. Please refer to the conflict of interests section at the end of this document.

Tuesday, May 27, 2025



Page	The Platform Group	Outperform			Price 12.		
Personne 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150	Software Germany	Upside 32.23%	40/00	10/04			40/07
Report Life 184 132 186 133 186 135 186 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 188 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>12/27e 1.51</td></th<>							12/27e 1.51
Medicangle probabe 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 1	Reported EPS		1.84				1.51
Formation 4,81 244 1.35 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.49 1.4			0.00				12.7% 0.00
Number of Application Congo 19.27 20.47 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42 20.42							1.48
Name of Michael Internation 1927 1928 2024 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928 1928							12.97
Manual Process							20.42 20.42
Denomination 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000	VALUATION (€m)			12/24	12/25e		12/27e
Part							
Resister Resister Resistance 915 131 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132						12.10	12.10
Meanting first water 11				169			247
Pener Pene							106
Protectors 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100							3.2 3.5
PE							0.0
PCF 1	Enterprise Value			269	358	354	352
Ne Yield Fe' yie							8.0
Fe/Pulard 19 19 19 19 19 19 19 1							6.4 0.0%
PR cont (VM) 128							12.3%
PASSIBLE OF A PRESENTED A PASSIBLE OF A PA	P/B incl. GW (x)			1.28	1.15	1.08	0.93
Content District 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150							0.93 0.42
EVERTOR SERTING 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150							5.4
	EV/Current EBIT (x)						6.4
Select			12/23	12/24	12/25	12/260	12/27e
Depositions	, ,						839
Current EBT							65
Published EIIT							-10.0 55
Companed Tax							55
Net income for quirty-accounted companies 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.							-9.6
Profit	·						-13.6 0.0
Monorly inferests 1.10							0.0
Adjact attributable net profit 31.2 40.1 27.3 27.8 27.8 27.8 27.8 27.8 27.8 27.8 27.8 27.8 27.8 27.8 27.8 27.8 27.8 27.8 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5							-1.0
December 1972 1274 1275 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 1276 127							30.8
Cond-will							30.8 12/27e
Inaplife fived assets 9,7 18,0 14,6 11.2 WCR 38,0 73,6 73,4 71,9 Financial assets 11,7 220 117 131 Ordinary shareholders equity 80,5 132 21,4 230 Minority interests 11,1 3.2 3.2 3.2 Shareholders equity 16,6 135 21,7 233 Non-current provisions 11,0 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,2 14,2 14,2 14,2 14,2							47.5
VCR NCR 38.0 73.5 73.4 71.9 Financial assets 11.7 22.0 11.7 23.0 12.2 21.2 23.0 12.2 23.0 23.2 23.2 23.2 23.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 53.2 50.0 53.2 53.2 53.2 50.0 53.2 50.0 53.2 53.2 53.2 50.0 53.2 50.0 53.2 50.0 53.2 50.0							94.5 7.8
Ordinary shareholders equity 80.5 13.2 21.4 23.0 Shareholders equity 81.6 13.5 21.7 23.3 Nan-current provisions 17.0 14.6 14.6 14.6 Net debt 68.5 10.1 11.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 10.0 12.7 12.7 10.0 12.7 11.7 11.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7 12.7							71.6
Minority interests 81.6 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.0 4.2 3.2 3.0 3.2 3.0 3.2 3.0 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2							167
Shareholders equity 14.6 13.5 21.7 23.8 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6							265 3.2
Net obs 12/23 12/24 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12/25 12							268
CASHEROW STATEMENT (Em)							14.6
BITDA 44.8 55.6 69.2 60.0 Change in WCR -38.0 -35.6 0.2 1.5 Interests & taxes 6.6 13.7 1.0 -2.5 Others 88.7 24.3 -38.7 -20.3 Operating Cash flow 104.1 57.9 31.8 38.7 CAPEX -21.0 -8.1 -8.2 -8.3 Free cash-flow 83.0 49.8 23.5 30.4 Acquisitions / disposals -58.8 -48.4 -40.0 0.0 Dividends 0.0 0.0 0.0 0.0 Mct capital increase 0.0 0.0 0.0 0.0 Others 4.0 -1.2 16.5 -15.5 CROWITH MARCINS PRODUCTIVITY 12/23 12/24 12/25e 12/26e Sales growth 1 1.7.2% 12.6 15.6 Lift sales growth - 1.7.2% 2.6 -1.5 Current EBIT growth - 1.7.2% <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>106 12/27e</td></td<>							106 12/27e
Interest's taxes							65.0
Chers 10,41 24,31 38,7 20,3 38,7 20,3 38,7 20,3 38,7 20,3 38,7 20,3 38,7 20,3 38,7 20,3 38,7 20,3 38,7 20,3 38,7 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3 20,3							0.3
Operating Cash flow 104.1 5.79, 31.8 38.7 CAPEX -21.0 -8.1 8.2 -8.3 Free cash-flow 83.0 49.8 23.5 30.4 Acquisitions / disposals -58.8 -48.4 -40.0 0.0 Dividends 0.0 0.0 0.0 0.0 Net capital increase 0.0 0.0 0.0 0.0 Others -4.0 -1.2 16.5 -15.5 Change in net cash 25.3 -32.1 -10.6 4.3 Change in net cash 25.3 -32.1 -10.6 4.3 Change in net cash 25.3 -32.1 -10.6 4.3 Change in net cash 25.3 -32.1 -10.6 4.2 Balse growth 1 <	Others						-4.0 -22.6
Free cash-flow 83.0 49.8 23.5 30.4 Acquisitions/disposals -58.8 -48.4 -40.0 0.0 Dividends 0.0 0.0 0.0 0.0 Net capital increase 0.0 0.0 0.0 0.0 Change in net cash 25.3 -3.2.1 -10.6 4.3 Change in net cash 12/3 12/2 12/25 12/26 Cown the MARGINSPRODUCTIVITY 12/23 12/24 12/25 12/26 Sales growth - 1.1.7 29.6% 15.5% Current EBIT growth - 17.7% 29.6% -15.5% Corwhin adjusted EPS - 17.7% 29.6% -15.6% Net margin 7.4% 5.9% 5.8% 3.4% EBITDA margin 10.8% 10.6% 10.0% 7.5% CAPEX/ Sales 4.9% 1.5% -1.2% -1.0% CAPEX/ Sales -1.1% 2.2% 17.3% 30.0% Tax Rate -1.1 <td>Operating Cash flow</td> <td></td> <td>104.1</td> <td>57.9</td> <td>31.8</td> <td>38.7</td> <td>38.7</td>	Operating Cash flow		104.1	57.9	31.8	38.7	38.7
Acquisitions/ disposals -58.8 -48.4 -40.0 0.0 Dividends 0.0 0.0 0.0 0.0 Net capital increase 0.0 0.0 0.0 0.0 Others -4.0 -1.2 16.5 -15.5 Change innet cash 25.3 -3.21 -10.6 4.3 Change innet cash 12/23 12/24 12/25 12/26 Sales growth - 21.4% 31.6% 16.2% Lif sales growth - 17.7% 29.6% 11.5% Growth in adjusted EPS - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -							-8.4
Dividends 0.0 0.0 0.0 0.0 Net capital increase 0.0 0.0 0.0 0.0 Others 4.40 -1.2 16.5 -15.5 Chage in net cash 25.3 -32.1 -10.6 4.3 Edin Sprobut 1.2 12.23 12.24 12.5e 12.7e Sales growth - 21.4% 31.6% 16.2e Lif sales growth - 1.7.7% 29.6% -1.56 Current EBIT growth - 1.7.7% 29.6% -1.56 Crowth in adjusted EPS - 17.2% 28.7% -31.9% Net margin 7.4% 5.9% 5.8% 3.4% Current EBIT margin 9.0% 8.7% 8.6% 6.2% CAPEX / Sales -4.9% 1.15% -1.2% 1.0% VCR / Sales -4.9% 1.5% -1.2% 1.0% VCR / Sales -3.0 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.							30.3 0.0
Others 4.0 1.12 1.6.5 1.15.5 Change in net cash 25.3 -32.1 -10.6 4.3 GROWTH MARGINS PRODUCTIVITY 12/28 12/24 12/25e 12/25e Sales growth - 2.1.4% 31.6% 16.2% Lif sales growth - - 1.7.7 29.6% -15.6% Current EBIT growth - 17.7% 29.6% -15.6% Growth in adjusted EPS - -17.2% 28.7% -31.9% Net margin 7.4% 5.9% 5.8% 3.4% BEITDA margin 10.8% 10.6% 10.0% 7.5% CMPK / Sales 4.9 1.5% 6.2% 1.0% CAPEX / Sales 4.9 1.5% 1.2% 1.0% WCR / Sales 4.9 1.5% 6.2% 1.0% Normative tax rate 3.0 3.0 3.0 9.0% Asset Turnover 2.7 3.0 3.6 1.0% 1.0% 1.0% 1.0% <td>·</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.0</td>	·						0.0
Change in net cash 25.3 -32.1 -10.6 4.3 CROWTH MARGINS PRODUCTIVITY 12/23 12/24 12/25e 12/26e Sales growth - 21.4% 31.6% 16.9% Lif sales growth - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -							0.0
Sales growth 12/23 12/24 12/25e 12/26e							-18.5 1.2
Lift sales growth - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -	GROWTH MARGINS PRODUCTIVITY			12/24	12/25e	12/26e	12/27e
Current EBIT growth - 17.7% 29.6% -15.6% Growth in adjusted EPS - -17.2% 28.7% -31.9% Net margin 7.4% 5.9% 5.8% 3.4% EBITDA margin 10.6% 10.0% 5.8% 3.4% Current EBIT margin 9.0% 8.7% 8.6% 6.2% CAPEX / Sales 4.9% -1.5% -1.2% -1.0% WCR / Sales 8.8% 1.0 10.6% 9.0% Tax Rate 8.8% 1.0 10.6% 9.0% Normative tax rate 30.0% 30.0% 30.0% 30.0% Asset Turnover 1.1% 2.2% 17.3% 30.0% ROCE post-tax (normative tax rate) 1.6% 18.3% 15.6% ROCE post-tax (normative tax rate) 2.1% 23.1% 15.6% ROE 2.1% 2.2% 23.2% 12.3% ROE 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% <td></td> <td></td> <td>-</td> <td>21.4%</td> <td>31.6%</td> <td>16.2%</td> <td>4.5%</td>			-	21.4%	31.6%	16.2%	4.5%
Growth in adjusted EPS 17.2% 28.7% -31.9% Net margin 7.4% 5.9% 5.8% 3.4% EBITDA margin 10.8% 10.6% 10.0% 7.5% Current EBIT margin 9.0% 8.7% 8.6% 6.2% CAPEX / Sales 4.9% 1.15% 1.2% 1.0% WCR / Sales 8.8% 14.0% 10.6% 9.0% Tax Rate 8.8% 14.0% 10.6% 9.0% Normative tax rate 30.0% 30.0% 30.0% 30.0% Asset Turnover 2.7 3.0 3.6 ROCE post-tax (normative tax rate) 2.7 3.0 3.6 ROCE post-tax (normative tax rate) 2.2 12.7% 15.6% ROE 2.1 2.2 2.3 12.3% 15.6% ROE 2.2 2.2 2.2 12.7 3.0 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.2 <t< td=""><td>•</td><td></td><td>- -</td><td>17.7%</td><td>29.6%</td><td>-15.6%</td><td>9.9%</td></t<>	•		- -	17.7%	29.6%	-15.6%	9.9%
EBITDA margin 10.8% 10.6% 10.0% 7.5% Current EBIT margin 9,0% 8.7% 8.6% 6.2% CAPEX/Sales 4,9% -1.5% -1.2% -1.0% WCR / Sales 8.8% 14,0% 10,0% 9.0% Tax Rate 1.1% 2.2% 17.3% 30.0% Normative tax rate 30.0% 30.0% 30.0% 30.0% Asset Turnover - 1.67 13.0 3.6 ROCE post-tax (normative tax rate) - 1.67 21.9% 23.1% 19.8% ROE 29.3% 23.2% 12.3% 12.9% 23.2% 12.3% DED TATION 12/23 12/24 12/25 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26	Growth in adjusted EPS		=	-17.2%	28.7%	-31.9%	12.7%
Current EBIT margin 9.0% 8.7% 8.6% 6.2% CAPEX / Sales -4.9% -1.5% -1.2% -1.0% WCR / Sales 8.8% 1.10 10.6% 9.0% Tax Rate -1.1% 2.2% 17.3% 30.0% Normative tax rate 30.0% 30.0% 30.0% 30.0% Asset Turnover - 2.7 3.0 3.6 ROCE post-tax (normative tax rate) - 16.7% 18.3% 15.6% ROCE post-tax (normative tax rate) - 2.19% 23.2% 12.3% ROE - 2.9.3% 23.2% 12.3% ROE - 2.9.3% 23.2% 12.3% DEBT RATIOS 12/23 12/24 12/25e 12/26e Gearing 84% 74% 51% 46% Net Debt / Market Cap 0.60 0.45 0.43	· ·						3.7% 7.8%
CAPEX/ Sales 4-4,9% -1.5% -1.2% -1.0% WCR / Sales 8.8% 14.0% 10.6% 9.0% Tax Rate -1.1% 2.2% 17.3% 30.0% Normative tax rate 30.0% 30.0% 30.0% 30.0% Asset Turnover - 2.7 3.0 3.6 ROCE post-tax (normative tax rate) - 2.19% 23.1% 15.6% ROE post-tax hors GW (normative tax rate) - 21.9% 23.2% 12.3% ROE - 29.3% 23.2% 12.3% Post fax In the Company of the Com							7.8% 6.6%
Tax Rate -1.1% 2.2% 17.3% 30.0% Normative tax rate 30.0% 30.0% 30.0% 30.0% Asset Turnover - 2.7 3.0 3.6 ROCE post-tax (normative tax rate) - 16.7% 18.3% 15.6% ROCE post-tax hors GW (normative tax rate) - 21.9% 23.1% 19.8% ROE 29.3% 23.2% 12.3% DEBT RATIOS 12/23 12/24 12/25e 12/26e Gearing 84% 74% 51% 46% Net Debt / Market Cap 0.60 0.45 0.43	CAPEX / Sales		-4.9%	-1.5%	-1.2%	-1.0%	-1.0%
Normative tax rate 30.0% 30.0% 30.0% 30.0% Asset Turnover - 2.7 3.0 3.6 ROCE post-tax (normative tax rate) - 16.7% 18.3% 15.6% ROCE post-tax hors GW (normative tax rate) - 21.9% 23.1% 19.8% ROE - 29.3% 23.2% 12.3% DEBT RATIOS 12/23 12/24 12/25e 12/26e Gearing 84% 74% 51% 46% Net Debt / Market Cap 6.6% 0.45 0.43							8.5% 30.0%
Asset Turnover - 2.7 3.0 3.6 ROCE post-tax (normative tax rate) - 16.7% 18.3% 15.6% ROCE post-tax hors GW (normative tax rate) - 21.9% 23.1% 19.8% ROE - 29.3% 23.2% 12.3% PER FATIOS 12/23 12/24 12/25e 12/26e Gearing 84% 74% 51% 46% Net Debt / Market Cap 0.60 0.45 0.43							30.0%
ROCE post-tax hors GW (normative tax rate) - 21.9% 23.1% 19.8% ROE 29.3% 23.2% 12.3% DEDT RATIOS 12/23 12/24 12/26 Gearing 84% 74% 51% 46% Net Debt / Market Cap 0.60 0.45 0.43	Asset Turnover		-	2.7	3.0	3.6	3.8
ROE 29.3% 23.2% 12.3% DEBT ARTIOS 12/23 12/24 12/25e 12/26e Gearing 84% 74% 51% 46% Net Debt / Market Cap 0.60 0.45 0.43			-				17.3% 22.0%
DEBT RATIOS 12/23 12/24 12/25e 12/26e Gearing 84% 74% 51% 46% Net Debt / Market Cap 0.60 0.45 0.43			-				12.4%
Net Debt / Market Cap 0.60 0.45 0.43	DEBT RATIOS			12/24	12/25e	12/26e	12/27e
			84%				39% 0.43
			1.47				1.63
EBITDA / net financial charges 7.3 5.9 7.2 6.2	EBITDA / net financial charges						6.8
Sources: ODDO BHF Securities, SIX	Sources: ODDO BHF Securities, SIX						

Tuesday, May 27, 2025



Valuation method

Our target prices are established on a 12-month timeframe and we use three valuation methods to determine them. First, the discounting of available cash flows using the discounting parameters set by the Group and indicated on ODDO BHF' website. Second, the sum-of-the-parts method based on the most pertinent financial aggregate depending on the sector of activity. Third, we also use the peer comparison method which facilitates an evaluation of the company relative to similar businesses, either because they operate in identical sectors (and are therefore in competition with one another) or because they benefit from comparable financial dynamics. A mixture of these valuation methods may be used in specific instances to more accurately reflect the specific characteristics of each company covered, thereby fine-tuning its evaluation.

• Sensitivity of the result of the analysis/ risk classification:

The opinions expressed in the financial analysis are opinions as per a particular date, i.e. the date indicated in the financial analysis. The recommendation (cf. explanation of the recommendation systematic) can change owing to unforeseeable events which may, for instance, have repercussions on both the company and on the whole industry.

· Our stock market recommendations

Our stock market recommendations reflect the RELATIVE performance expected for each stock on a 12-month timeframe. Outperform: performance expected to exceed that of the benchmark index, sectoral (large caps) or other (small and mid caps). Neutral: performance expected to be comparable to that of the benchmark index, sectoral (large caps) or other (small and mid caps). Underperform: performance expected to fall short of that of the benchmark index, sectoral (large caps) or other (small and mid caps).

- The prices of the financial instruments used and mentioned in this document are the closing prices.
- · All publications by ODDO BHF concerning the companies covered and mentioned in this document are available on the research site: www.securities.oddobhf.com/#disclaimer.

Recommendation and target price changes history over the last 12 months for the company analysed in this report					
Date	Reco	Price Target (EUR)	Price (EUR)	Analyst	
02/05/25	Outperform	16.00	10.30	Klaus Breitenbach	
27/11/24	Outperform	13.50	7.20	Klaus Breitenbach	
23/07/24	Outperform	12.50	8.64	Klaus Breitenbach	

In accordance with Article 20 of European Regulation No. 596/2014 (Market Abuse Regulation), a list of all recommendations on any financial instrument or issuer that have been disseminated over the past twelve months is available by clicking on the following link www.securities.oddo-bhf.com/# disclaimer.

	Outperform	Neutral	Underperform
(776)	51%	40%	9%
(120)	47%	43%	11%
(72)	56%	38%	7%
(45)	69%	27%	4%
	(120) (72)	(776) 51% (120) 47% (72) 56%	(776) 51% 40% (120) 47% 43% (72) 56% 38%

Risk of conflict of interest:	
Investment banking and/or Distribution	If yes, specify the name of the issuers concerned
Has ODDO BHF SCA or its affiliates managed or co-managed in the last 12 months a public offering of securities for the subject company/ies?	No
Has ODDO BHF SCA or its affiliates received compensation for other investment banking services from the subject company/ies in the last 12 months or expects to receive or intends to seek compensation for other investment banking services from the subject company/ies in the last 12 months?	No
Research contract between ODDO group & the issuer	If yes, specify the name of the issuers concerned
Have ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. and the subject company/ies agreed that ABN AMRO - ODDO BHF B.V. or one of its parent companies will produce and disseminate investment recommendations on the subject company/ies as a service to the the subject company/ies?	No
Liquidity provider agreement and market-making	If yes, specify the name of the issuers concerned
At the date of the distribution of this report does ODDO BHF SCA or its affiliates act as a market maker or has ODDO BHF SCA or its affiliates signed a liquidity provider agreement with the subject company/ies?	No

Significant equity stake	If yes, specify the nam of the issuers concern
Does ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. own 1% or more of any class of common equity securities of the subject company/ies?	No
One or more affiliates of ODDO BHF SCA other than ABN AMRO – ODDO BHF B.V. from time to time may own 1% or more of a class of common equity securities of the subject company/ies.	No
Does ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. own a net long or short position of 0.5% or more of any class of common equity securities of the subject company/ies?	No
Does the subject company beneficially own 5% or more of any class of common equity of ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V.?	No

Disclosure to Company

Tuesday, May 27, 2025



Has the financial analysis been sent to the issuer for verification prior to publication?	No
Have any modifications been made to the conclusions of the analysis following its verification by the issuer?	No
Additional material conflicts	
Is ODDO BHF SCA or its affiliates aware of any additional material conflict of interest?	No
Personal conflicts of interest	
Do you buy or sell financial instruments from the issuer(s) concerned by this financial analysis?	No
Have those responsible for the drafting of the present document received remuneration directly linked to investment firm service transactions or any other kind of transaction they carry out or any trading commissions they or any legal person who is part of the same group receive?	No

 $Statement\ of\ conflict\ of\ interests\ of\ all\ companies\ mentioned\ in\ this\ document\ may\ be\ consulted\ on\ ODDO\ BHF:\ www.securities.oddo-bhf.com/\# disclaimer.$

Tuesday, May 27, 2025

Disclaimer:



Disclaimers for Distribution by ODDO BHF SCA to Non-United States Investors:

This research publication is produced by the Corporates & Markets division of ODDO BHF SCA ("ODDO"), which is licensed by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the Autorité des Marchés Financiers ("AMF").

The research, when distributed outside of the U.S., is intended exclusively for non-U.S. customers of ODDO and cannot be divulged to a third-party without prior written consent of ODDO. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French regulatory provisions designed to promote the independence of investment research. The recommendation presented in this document is reviewed and updated at least quarterly following each Quarterly Report published by the issuer that is the subject of this Research Report.

At the time of publication of this document, ODDO and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context which is subject to change without notice. The views expressed in this Research Report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the Research Report. This Research Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice.

This Research Report is for institutional investors only. It may not contain information necessary for others to make investment decisions. Consult your financial adviser or an investment professional if you are not an institutional investor.

Disclaimers for Distribution by ODDO BHF New York Corporation to United States Investors:

This Research Report is produced by ODDO BHF Corporates & Markets, a division of ODDO. This research is distributed to U.S. investors exclusively by ODDO BHF New York Corporation ("ONY"), MEMBER: FINRA/SIPC, and is intended exclusively for U.S. customers of ONY and cannot be divulged to a third-party without prior written consent of ONY. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French regulatory provisions designed to promote the independence of investment research. The recommendation presented in this document is reviewed and updated at least quarterly following each Quarterly Report published by the issuer that is the subject of this Research Report.

At the time of publication of this document, ODDO, and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context which is subject to change without notice. The views expressed in this Research Report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the Research Report. This Research Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice.

This Research Report is for institutional investors only. It may not contain information necessary for others to make investment decisions. Consult your financial adviser or an investment professional if you are not an institutional investor.

Disclosures Required by United States Laws and Regulations:

Rule 15a-6 Disclosure: Under Rule 15a-6(a)(3), any transactions conducted by ODDO, and/or one of its subsidiaries with U.S. persons in the securities described in this foreign research must be effected through ONY. As a member of FINRA, ONY has reviewed this material for distribution to U.S. persons as required by FINRA Rules 2241(h) applicable to dissemination of research produced by its affiliate ODDO.

FINRA Disclosures:

- Neither ONY, ODDO, nor ODDO BHF Corporates & Markets beneficially owns 1% or more of any class of common equity securities of the subject company.
- The research analyst of ODDO BHF Corporates & Markets, at the time of publication of this research report, is not aware, nor does he or she know or have reason to know of any actual, material conflict of interest of himself or herself, ODDO, ODDO BHF Corporates & Markets or ONY, except those mentioned in the paragraph entitled "Risks of Conflicts of Interest"
- ODDO BHF Corporates & Markets or ODDO may receive or seek compensation for investment banking services in the next 3 months from the subject company of this Research Report, but ONY would not participate in those arrangements.
- Neither ONY, ODDO, ODDO BHF Corporates & Markets has received compensation from the subject company in the past 12 months for providing investment banking services except those mentioned in the paragraph of "Risks of Conflict of Interest"."
- Neither ONY, ODDO, ODDO BHF Corporates & Markets has managed or co-managed a public offering of securities for the subject company in the past 12 months except those mentioned in the paragraph of "Risk of Conflict of Interest".
- ONY does not make (and never has made) markets and, accordingly, was not making a market in the subject company's securities at the time that this research report was published.

Regulation AC:

ONY is exempt from the certification requirements of Regulation AC for its distribution to a U.S. person in the United States of this Research Report that is prepared by an ODDO BHF Corporates & Markets research analyst because ODDO has no officers or persons performing similar functions or employees in common with ONY and ONY maintains and enforces written policies and procedures reasonably designed to prevent it, any controlling persons, officers or persons performing similar functions, and employees of ONY from influencing the activities of the third party research analyst and the content of research reports prepared by the third party research analyst.

Contact Information of firm distributing research to U.S. investors: ODDO BHF New York Corporation, MEMBER: FINRA/SIPC, is a wholly owned subsidiary of ODDO BHF SCA; Louis paul ROGER, President (louis-paul.roger@oddo-bhf.com) 150 East 52nd Street New York, NY 10022 646-286-2137.

Statement of conflict of interests of all companies mentioned in this document may be consulted on Oddo BHF research site.